TORONTO – In recent past, Health Canada approved Trulicity® (dulaglutide) to reduce the risk of non-fatal stroke in adults with type 2 diabetes mellitus who have multiple cardiovascular risk factors or established cardiovascular disease, as an adjunct to diet, exercise, and standard of care therapy. This decision makes Eli Lilly and Company’s Trulicity the first and only GLP1 receptor agonist (RA) approved …
Toronto – Eli Lilly Canada announced approval of Trulicity (dulaglutide), a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist indicated for the treatment of adults with type 2 diabetes to improve glycemic control. GLP-1 is a naturally occurring intestinal hormone that is released when people eat, causing reduced appetite and the release of insulin.1 Trulicity is delivered in a pre-filled, single-use pen with …
